Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

Background Melanoma of unknown primary (MUP) represents a poorly understood group of patients both clinically and immunologically. We investigated differences in prognosis and candidate immune biomarkers in patients with unknown compared with those with known primary melanoma enrolled in the E1609 a...

Full description

Bibliographic Details
Main Authors: Butterfield, L.H (Author), Conejo-Garcia, J.R (Author), El Naqa, I.M (Author), Hwu, P. (Author), Karunamurthy, A.D (Author), Kirkwood, J.M (Author), Laframboise, W.A (Author), Lee, S.J (Author), Sondak, V.K (Author), Stephen Hodi, F. (Author), Storkus, W.J (Author), Streicher, H. (Author), Tan, A.-C (Author), Tarhini, A.A (Author)
Format: Article
Language:English
Published: BMJ Publishing Group 2022
Subjects:
adolescent
Adolescent
adult
Adult
alpha interferon
Article
B lymphocyte
blood sampling
cancer of unknown primary site
cancer prognosis
CD4+ T lymphocyte
CD8+ T lymphocyte
child
Child
clinical trial
controlled study
flow cytometry
gene expression profiling
Gene Expression Profiling
gene set enrichment analysis
human
human cell
human tissue
Humans
immunology
interleukin 2 receptor
ipilimumab
KEGG
major histocompatibility antigen class 1
major histocompatibility antigen class 2
melanoma
Melanoma
mortality
natural killer cell
Neoplasms, Unknown Primary
overall survival
pathology
phase 3 clinical trial
phase 3 clinical trial (topic)
randomized controlled trial
randomized controlled trial (topic)
recurrence free survival
Skin Neoplasms
skin tumor
survival rate
tumor associated leukocyte
tumor biopsy
tumor immunogenicity
tumor microenvironment
young adult
Young Adult
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items